Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-targeted CAR-T in Refractory Juvenile Dermatomyositis
NCT06569472Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in juvenile dermatomyositis (JDM), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety and Tolerability of CAR-T at 28 days, Efficacy of CAR-T at 3 months and 1 more. Started Jul 2024; status: recruiting.
02
Conditions
juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on NCT06569472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569472.